Dual-target CD19/BCMA CAR-T approaches overcome these limitations by additionally depleting plasma cells, eliminating pre-existing autoreactive clones, and reducing inflammatory pathways, offering a more comprehensive reset of B-cell-driven autoimmunity. Here, CD19 is linked to Autoimmunity.